RITA Medical CEO to Present at the RBC Capital Markets 2006 Healthcare Conference
07 Diciembre 2006 - 12:00PM
PR Newswire (US)
FREMONT, Calif., Dec. 7 /PRNewswire-FirstCall/ -- RITA Medical
Systems, Inc. (NASDAQ:RITA), a publicly-traded medical device
company focused solely on cancer therapies, today announced that
Joseph DeVivo, President & CEO of RITA Medical Systems, will
participate in the panel discussion "Away From the Heart: Expanding
the Role of Interventional Medicine" at the RBC Capital Markets
2006 Healthcare Conference. The presentation is scheduled for 12:30
p.m. Eastern Time on Wednesday, December 13, 2006 and will take
place at the Westin New York at Times Square Hotel. Attendance at
the conference is by invitation only. RITA Medical will offer a
live audio webcast of this presentation which may be accessed at
the Company's website at http://www.ritamedical.com/. An archived
replay of the presentation will be made available as soon as
practicable following the completion of the live presentation and
will also be available at http://www.ritamedical.com/ for 30 days.
About RITA Medical Systems, Inc. RITA Medical Systems develops,
manufactures and markets innovative products for cancer patients
including radiofrequency ablation (RFA) systems and embolization
products for treating cancerous tumors as well as percutaneous
vascular and spinal access systems. The Company's oncology product
lines include implantable ports, some of which feature its
proprietary Vortex(R) technology; tunneled central venous
catheters; and safety infusion sets and peripherally inserted
central catheters used primarily in cancer treatment protocols. The
radiofrequency product line also includes the HABIB 4X resection
device which coagulates a "surgical resection plane" and is
designed to facilitate a fast dissection in order to minimize blood
loss and blood transfusion during surgery. The proprietary RITA RFA
system uses radiofrequency energy to heat tissue to a high enough
temperature to ablate it or cause cell death. In March 2000, RITA
became the first RFA company to receive specific FDA clearance for
unresectable liver lesions in addition to its previous general FDA
clearance for the ablation of soft tissue. In October 2002, RITA
again became the first company to receive specific FDA clearance,
this time for the palliation of pain associated with metastatic
lesions involving bone. The Company also distributes LC Bead(TM)
embolic microspheres in the United States. The LC Bead microspheres
are injected into selected vessels to block the blood flow feeding
a tumor, causing it to shrink over time, and are often used in
combination with RFA. The RITA Medical Systems website is at
http://www.ritamedical.com/. Contact: EVC Group Investors: Doug
Sherk Jenifer Kirtland 415-896-6820 Media: Steve DiMattia
646-277-8706 RITA Medical Systems, Inc. Stephen Pedroff, VP
Marketing Communications 510-771-0400 DATASOURCE: RITA Medical
Systems, Inc. CONTACT: media, Steve DiMattia, +1-646-277-8706, or ,
or investors, Doug Sherk, , or Jenifer Kirtland, , both of EVC
Group, +1-415-896-6820, for RITA Medical Systems, Inc.; or Stephen
Pedroff, VP Marketing Communications of RITA Medical Systems, Inc.,
+1-510-771-0400 Web site: http://www.ritamedical.com/
Copyright
Rita Medical (NASDAQ:RITA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Rita Medical (NASDAQ:RITA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Rita Medical Systems (NASDAQ): 0 recent articles
Más de Rita Medical Systems (MM) Artículos de Noticias